Log In
Print
BCIQ
Print
Print this Print this
 

Oblean, cetilistat (Cametor) (ATL-962)

  Manage Alerts
Collapse Summary General Information
Company Norgine B.V.
DescriptionOral lipase inhibitor
Molecular Target Lipase
Mechanism of ActionLipase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationObesity
Indication DetailsTreat obesity; Treat obesity in diabetic patients; Treat obesity in patients with complications; Treat obesity in patients with Type II diabetes and dyslipidemia
Regulatory Designation

Japan - Standard Review (Treat obesity in patients with Type II diabetes and dyslipidemia)

Partner

Takeda Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today